How to reduce morbidity and mortality from chest infections in rheumatoid arthritis

Author： Housden MM   Bell G   Heycock CR   Hamilton J   Saravanan V   Kelly CA  

Publisher： Royal College Of Physicians

ISSN： 1470-2118

Source： Clinical Medicine, Vol.10, Iss.4, 2010-08, pp. : 326-329

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

How does rheumatoid arthritis need to be managed?

By Deighton Chris   Rudolf Michael  

Clinical Medicine, Vol. 10, Iss. 2, 2010-04 ,pp. : 151-153

Royal College Of Physicians

Access to resources Recommend Favorite

Valsartan can reduce the combined mortality and morbidity risk in patients with heart failure

By  

Inpharma, Vol. 1, Iss. 1318, 2001-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis

By Brinkman Ithamar Heber   Laar Mart AFJ van de   Jansen Tim L   van Roon Eric N  

Expert Opinion on Drug Safety, Vol. 10, Iss. 5, 2011-09 ,pp. : 715-726

Informa Healthcare

Access to resources Recommend Favorite

Interleukin-6 In Rheumatoid Arthritis - From The Laboratory To The Bedside

By  

Current Pharmaceutical Design, Vol. 21, Iss. 17, 2015-05 ,pp. : 2187-2197

Bentham Science Publishers

Access to resources Recommend Favorite

How should TNF inhibitors be used in rheumatoid arthritis?

By  

Inpharma, Vol. 1, Iss. 1250, 2000-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite